JP2013526572A5 - - Google Patents

Download PDF

Info

Publication number
JP2013526572A5
JP2013526572A5 JP2013511293A JP2013511293A JP2013526572A5 JP 2013526572 A5 JP2013526572 A5 JP 2013526572A5 JP 2013511293 A JP2013511293 A JP 2013511293A JP 2013511293 A JP2013511293 A JP 2013511293A JP 2013526572 A5 JP2013526572 A5 JP 2013526572A5
Authority
JP
Japan
Prior art keywords
polymer compound
vinyl acetate
eye
ethylene
compound part
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013511293A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013526572A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/036806 external-priority patent/WO2011146483A1/en
Publication of JP2013526572A publication Critical patent/JP2013526572A/ja
Publication of JP2013526572A5 publication Critical patent/JP2013526572A5/ja
Pending legal-status Critical Current

Links

JP2013511293A 2010-05-17 2011-05-17 眼治療薬の送達のための薬物送達装置 Pending JP2013526572A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34554710P 2010-05-17 2010-05-17
US61/345,547 2010-05-17
PCT/US2011/036806 WO2011146483A1 (en) 2010-05-17 2011-05-17 Drug delivery devices for delivery of ocular therapeutic agents

Publications (2)

Publication Number Publication Date
JP2013526572A JP2013526572A (ja) 2013-06-24
JP2013526572A5 true JP2013526572A5 (cg-RX-API-DMAC10.html) 2014-07-03

Family

ID=44992020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013511293A Pending JP2013526572A (ja) 2010-05-17 2011-05-17 眼治療薬の送達のための薬物送達装置

Country Status (6)

Country Link
US (6) US20130142858A1 (cg-RX-API-DMAC10.html)
EP (1) EP2571526B1 (cg-RX-API-DMAC10.html)
JP (1) JP2013526572A (cg-RX-API-DMAC10.html)
AU (1) AU2011256259A1 (cg-RX-API-DMAC10.html)
CA (1) CA2798084A1 (cg-RX-API-DMAC10.html)
WO (1) WO2011146483A1 (cg-RX-API-DMAC10.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
EP3785683B1 (en) 2009-05-18 2023-11-01 Dose Medical Corporation Drug eluting ocular implant
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP4108216A1 (en) 2009-06-03 2022-12-28 Forsight Vision5, Inc. Anterior segment drug delivery
EP2571526B1 (en) 2010-05-17 2019-03-13 Novaer Holdings, Inc. Drug delivery devices for delivery of ocular therapeutic agents
EP2654715B1 (en) 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
CN103748139B (zh) 2011-06-23 2016-08-17 帝斯曼知识产权资产管理有限公司 用于递送生物活性剂的包含生物可降解的聚酯酰胺共聚物的微米颗粒或纳米颗粒
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
WO2013040238A2 (en) * 2011-09-13 2013-03-21 Vista Scientific Llc Sustained release ocular drug delivery devices and methods of manufacture
CN103917202B (zh) 2011-09-14 2016-06-29 弗赛特影像5股份有限公司 眼插入件装置和方法
US20150038415A1 (en) * 2011-12-16 2015-02-05 Dsm Ip Assets B.V. Process for the manufacturing of a drug delivery system based on a polymer comprising a dispersed bioactive agent
US8900300B1 (en) 2012-02-22 2014-12-02 Omega Ophthalmics Llc Prosthetic capsular bag and method of inserting the same
EP2903592B1 (en) 2012-10-02 2019-01-23 DSM IP Assets B.V. Drug delivery composition comprising proteins and biodegradable polyesteramides
WO2014066775A1 (en) 2012-10-26 2014-05-01 Forsight Vision5, Inc. Ophthalmic system for sustained release of drug to eye
US10098836B2 (en) 2013-05-02 2018-10-16 Retina Foundation Of The Southwest Method for forming a molded two-layer ocular implant
WO2015184173A1 (en) 2014-05-29 2015-12-03 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
AU2015277207B2 (en) 2014-06-19 2018-03-29 Omega Ophthalmics Llc Prosthetic capsular devices, systems, and methods
EP3223793B1 (en) * 2014-11-25 2023-06-28 Eximore Ltd. Compositions and methods for delivering a bio-active agent or bio-active agents
JP6720447B2 (ja) 2014-12-18 2020-07-08 ディーエスエム アイピー アセッツ ビー．ブイ．Ｄｓｍ Ｉｐ Ａｓｓｅｔｓ Ｂ．Ｖ． 酸感受性薬剤の送達のための薬剤送達系
US9358103B1 (en) * 2015-02-10 2016-06-07 Omega Ophthalmics Llc Prosthetic capsular devices, systems, and methods
WO2016168141A1 (en) 2015-04-13 2016-10-20 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
WO2016187355A1 (en) * 2015-05-20 2016-11-24 Glaukos Corporation Therapeutic drug compositions and implants for delivery of same
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
PT109154B (pt) * 2016-02-12 2019-11-05 Univ De Coimbra Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos
WO2017184881A1 (en) 2016-04-20 2017-10-26 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
EP3463189B1 (en) 2016-06-06 2023-01-18 Omega Ophthalmics LLC Prosthetic capsular device
EP3528747B1 (en) 2016-10-21 2021-09-15 Omega Ophthalmics LLC Prosthetic capsular devices
KR20200069261A (ko) * 2017-05-30 2020-06-16 엑시모어 엘티디. 항생제 마크로라이드를 전달하는 안구건조증을 치료하기 위한 조성물 및 방법
EP3773334A4 (en) 2018-04-06 2021-12-29 Omega Ophthalmics LLC Prosthetic capsular devices, systems, and methods
WO2019222856A1 (en) 2018-05-24 2019-11-28 Nureva Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
CA3087238A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
BR112020023982A2 (pt) 2018-05-24 2021-02-23 Celanese Eva Performance Polymers Llc dispositivo implantável para liberação prolongada de um composto de fármaco macromolecular
EP3810082A1 (en) * 2018-06-19 2021-04-28 Cella Therapeutics, LLC Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
EP3990042A4 (en) 2019-06-27 2023-07-19 Layerbio, Inc. METHODS AND SYSTEMS FOR RELEASING EYE DEVICES
WO2022082170A1 (en) 2020-10-12 2022-04-21 Omega Ophthalmics Llc Prosthetic capsular devices, systems, and methods
US12186512B2 (en) * 2020-10-26 2025-01-07 Christopher Green Treatment for dry eyes
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
WO2024258996A1 (en) * 2023-06-16 2024-12-19 Baylor College Of Medicine Ocular drug delivery

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3416530A (en) 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3618604A (en) 1969-06-09 1971-11-09 Alza Corp Ocular insert
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3993071A (en) 1971-09-09 1976-11-23 Alza Corporation Bioerodible ocular device
US3986510A (en) 1971-09-09 1976-10-19 Alza Corporation Bioerodible ocular device
US3981303A (en) 1971-09-09 1976-09-21 Alza Corporation Bioerodible ocular device
US3828777A (en) 1971-11-08 1974-08-13 Alza Corp Microporous ocular device
US3948254A (en) 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
SE375007B (cg-RX-API-DMAC10.html) 1972-11-30 1975-04-07 Pharmacia Ab
US4177256A (en) 1973-04-25 1979-12-04 Alza Corporation Osmotic bursting drug delivery device
US3961628A (en) 1974-04-10 1976-06-08 Alza Corporation Ocular drug dispensing system
US4135514A (en) 1974-12-23 1979-01-23 Alza Corporation Osmotic releasing system for administering ophthalmic drug to eye of animal
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4144317A (en) 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4052505A (en) 1975-05-30 1977-10-04 Alza Corporation Ocular therapeutic system manufactured from copolymer
US4057619A (en) 1975-06-30 1977-11-08 Alza Corporation Ocular therapeutic system with selected membranes for administering ophthalmic drug
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4391797A (en) 1977-01-05 1983-07-05 The Children's Hospital Medical Center Systems for the controlled release of macromolecules
US4164560A (en) 1977-01-05 1979-08-14 Folkman Moses J Systems for the controlled release of macromolecules
US4186184A (en) 1977-12-27 1980-01-29 Alza Corporation Selective administration of drug with ocular therapeutic system
US4190642A (en) 1978-04-17 1980-02-26 Alza Corporation Ocular therapeutic system for dispensing a medication formulation
US4281654A (en) 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
US4278087A (en) 1980-04-28 1981-07-14 Alza Corporation Device with integrated operations for controlling release of agent
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4753652A (en) 1984-05-04 1988-06-28 Children's Medical Center Corporation Biomaterial implants which resist calcification
US4663147A (en) 1985-09-03 1987-05-05 International Minerals & Chemical Corp. Disc-like sustained release formulation
CA1330886C (en) 1988-01-22 1994-07-26 Bend Research Inc. Osmotic system for delivery of dilute solutions
US5185152A (en) 1990-01-10 1993-02-09 Peyman Gholam A Method and apparatus for controlled release drug delivery to the cornea and anterior chamber of the eye
AU7998091A (en) 1990-05-17 1991-12-10 Harbor Medical Devices, Inc. Medical device polymer
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5302397A (en) 1991-11-19 1994-04-12 Amsden Brian G Polymer-based drug delivery system
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
FR2692812B1 (fr) 1992-06-24 1994-12-30 Flamel Tech Sa Microcapsules contenant au moins un principe actif, leurs applications et procédé de préparation de microcapsules renfermant au moins un principe actif.
US20030203976A1 (en) 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
EP1652539B8 (en) 1993-07-19 2011-06-15 Angiotech Pharmaceuticals, Inc. Method of manufacturing a stent comprising an anti-angiogenic composition
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5877224A (en) 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6196993B1 (en) * 1998-04-20 2001-03-06 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye
US6423345B2 (en) 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
EP1554990A3 (en) 1999-01-29 2008-08-06 Medtronic, Inc. Implantable medical device with enhanced biocompatibility and biostability
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
TR200201047T2 (tr) 1999-10-21 2002-07-22 Alcon, Inc. İlaç verme vasıtası.
IL143477A (en) 2001-05-31 2009-07-20 Finetech Pharmaceutical Ltd Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
US20040208910A1 (en) * 2000-04-26 2004-10-21 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
AU3649502A (en) 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US6756058B2 (en) * 2001-01-03 2004-06-29 Bausch & Lomb Incorporated Sustained release drug delivery devices with multiple agents
US6713081B2 (en) 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
BR0205990A (pt) 2001-08-29 2004-01-13 Ricardo Azevedo Ponte Carvalho Um sistema implantável de liberação unidirecional de agentes terapêuticos para tecidos
US20030059466A1 (en) 2001-09-14 2003-03-27 Pawan Seth Delayed release tablet of venlafaxin
MXPA05007718A (es) * 2003-01-24 2005-09-30 Control Delivery Sys Inc Dispositivo de liberacion sostenida y metodo para la administracion ocular de inhibidores de anhidrasa carbonica.
US20050079199A1 (en) 2003-02-18 2005-04-14 Medtronic, Inc. Porous coatings for drug release from medical devices
US20060167435A1 (en) 2003-02-18 2006-07-27 Adamis Anthony P Transscleral drug delivery device and related methods
JP4898431B2 (ja) 2003-04-29 2012-03-14 ザ ジェネラル ホスピタル コーポレイション 複数薬物の持続放出のための方法およびデバイス
DK1696822T3 (da) 2003-11-13 2010-05-17 Psivida Inc Injicerbart vedvarende frigørelsesimplantat, som har en bioeroderbar matrixkerne og en bioeroderbar hus
US7211272B2 (en) 2003-12-22 2007-05-01 Bausch & Lomb Incorporated Drug delivery device
US7976858B2 (en) 2004-01-13 2011-07-12 The Hospital For Special Surgery Drug delivery to a joint
GB0401947D0 (en) 2004-01-28 2004-03-03 Unilever Plc Porous bodies and method of production thereof
SG150501A1 (en) 2004-02-05 2009-03-30 Millipore Corp Porous adsorptive or chromatographic media
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US7820732B2 (en) 2004-04-30 2010-10-26 Advanced Cardiovascular Systems, Inc. Methods for modulating thermal and mechanical properties of coatings on implantable devices
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
JP2008509240A (ja) 2004-08-03 2008-03-27 エイジェンシー フォー サイエンス，テクノロジー アンド リサーチ 薬物送達のための連続孔を有するポリマー及び方法
FR2875409B1 (fr) 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
US20060247266A1 (en) * 2004-11-26 2006-11-02 Asahi Kasei Pharma Corporation Nitrogen-containing tricyclic compounds
US20060134174A1 (en) 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US20070009564A1 (en) 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
US20070212397A1 (en) 2005-09-15 2007-09-13 Roth Daniel B Pharmaceutical delivery device and method for providing ocular treatment
DE602006005826D1 (de) 2005-09-21 2009-04-30 Univ Aston Chronotherapeutisches okulares abgabesystem aus einer kombination von prostaglandinen und einem betablocker zur behandlung von primärem glaukom
US20070260203A1 (en) 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20080057103A1 (en) 2006-08-21 2008-03-06 Wouter Roorda Methods of using medical devices for controlled drug release
CA2688389A1 (en) 2007-06-06 2008-12-11 Basf Se Pharmaceutical formulation for the production of rapidly disintegrating tablets
DE102008012295A1 (de) 2008-03-03 2009-09-17 Südzucker AG Mannheim/Ochsenfurt Gemisch zur Herstellung von schnell zerfallenden Tabletten
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US8722739B2 (en) * 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20100158980A1 (en) 2008-12-18 2010-06-24 Casey Kopczynski Drug delivery devices for delivery of therapeutic agents
CA2785468A1 (en) 2009-12-23 2011-06-30 Psivida Us, Inc. Sustained release delivery devices
CA2795706A1 (en) 2010-04-06 2011-10-13 Allergan, Inc. Sustained-release reservoir implants for intracameral drug delivery
EP2571526B1 (en) 2010-05-17 2019-03-13 Novaer Holdings, Inc. Drug delivery devices for delivery of ocular therapeutic agents

Similar Documents

Publication Publication Date Title
JP2013526572A5 (cg-RX-API-DMAC10.html)
JP2017524685A5 (cg-RX-API-DMAC10.html)
IL294463A (en) Methods for treating or preventing eye conditions
WO2011107855A3 (en) Sustained release oral liquid suspension dosage form
WO2014165308A3 (en) Microsphere drug delivery system for sustained intraocular release
JP2017522292A5 (cg-RX-API-DMAC10.html)
JP2015025011A5 (cg-RX-API-DMAC10.html)
JP2009501797A5 (cg-RX-API-DMAC10.html)
PH12019550088A1 (en) Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
JP2012521997A5 (cg-RX-API-DMAC10.html)
JP2012533517A5 (cg-RX-API-DMAC10.html)
JP2013006877A5 (cg-RX-API-DMAC10.html)
WO2016172712A3 (en) Ophthalmic composition
RU2018128980A (ru) Офтальмологические составы для доставки лекарственных средств к заднему сегменту глаза
JP2017532363A5 (cg-RX-API-DMAC10.html)
JP2011520805A5 (cg-RX-API-DMAC10.html)
JP2014139241A5 (cg-RX-API-DMAC10.html)
JP2011529854A5 (cg-RX-API-DMAC10.html)
AR070824A1 (es) Suspensiones para inyeccion intravitrea de triamcinolona acetonido de baja viscosidad, altamente floculadas
JP2014012746A5 (cg-RX-API-DMAC10.html)
WO2014106116A3 (en) Therapeutic compositions comprising antibodies
WO2015099985A3 (en) Cationic materials and formulations for drug delivery
JP2018507252A5 (cg-RX-API-DMAC10.html)
JP2013534527A5 (cg-RX-API-DMAC10.html)
JP2014515383A5 (cg-RX-API-DMAC10.html)